As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.
Bridget Mulvenna
Advertisement
Articles by Bridget Mulvenna
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist
2
Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline
3
What Trends Did You See at This Year's JP Morgan Healthcare Conference?
4
Pediatricians Mostly Side With AAP Over CDC in Vaccine Guidance Debate: Report
5